Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms

Molecular Therapy

Volumn 18, Issue 11, 2010, Pages 1947-1959

  Fridlender, Zvi G ^a,b   Sun, Jing ^a   Singhal, Sunil ^a   Kapoor, Veena ^a   Cheng, Guanjun ^a   Suzuki, Eiji ^a,c   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2A INTERFERON; BETA INTERFERON; CD8 ANTIGEN; CISPLATIN; GEMCITABINE; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MEMORY CELL; MONOTHERAPY; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

ANIMALIA;

EID: 78049479930     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.159     Document Type: Article

References (50)

1. Harris, J, Sengar, D, Stewart, T and Hyslop, D (1976). The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37(2 suppl): 1058-1069.
2. Gulley, JL, Madan, RA and Arlen, PM (2007). Enhancing effcacy of therapeutic vaccinations by combination with other modalities. Vaccine 25 (suppl 2): B89-B96.
3. Nowak, AK, Robinson, BW and Lake, RA (2003). Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496.
4. Ramakrishnan, R, Antonia, S and Gabrilovich, DI (2008). Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 57: 1523-1529.
5. Van Der Most, RG, Currie, A, Robinson, BW and Lake, RA (2006). Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66: 601-604.
6. Zitvogel, L, Apetoh, L, Ghiringhelli, F and Kroemer, G (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73.
7. Zitvogel, L, Apetoh, L, Ghiringhelli, F, André, F, Tesniere, A and Kroemer, G (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118: 1991-2001.
8. Lake, RA and Robinson, BW (2005). Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5: 397-405.
9. Antonia, SJ, Mirza, N, Fricke, I, Chiappori, A, Thompson, P, Williams, N et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12(3 Pt 1): 878-887.
10. Gribben, JG, Ryan, DP, Boyajian, R, Urban, RG, Hedley, ML, Beach, K et al. (2005). Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11: 4430-4436.
11. Arlen, PM, Gulley, JL, Parker, C, Skarupa, L, Pazdur, M, Panicali, D et al. (2006). A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269.
12. Gilboa, E (2004). The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
13. Harrop, R and Carroll, MW (2006). Viral vectors for cancer immunotherapy. Front Biosci 11: 804-817.
14. Sterman, DH, Recio, A, Carroll, RG, Gillespie, CT, Haas, A, Vachani, A et al. (2007). A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13(15 Pt 1): 4456-4466.
15. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721.
16. Zhong, H, Han, B, Tourkova, IL, Lokshin, A, Rosenbloom, A, Shurin, MR et al. (2007). Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 13(18 Pt 1): 5455-5462.
17. Pardoll, D (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839.
18. Curiel, TJ (2008). Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241-246.
19. + T cells. J Clin Invest 116: 2777-2790.
20. Kim, S, Fridlender, ZG, Dunn, R, Kehry, MR, Kapoor, V, Blouin, A et al. (2008). B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 31: 446-457.
21. Nowak, AK, Lake, RA, Marzo, AL, Scott, B, Heath, WR, Collins, EJ et al. (2003). Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specifc CD8 T cells. J Immunol 170: 4905-4913.
22. Haas, AR, Sun, J, Vachani, A, Wallace, AF, Silverberg, M, Kapoor, V et al. (2006). Cycloxygenase-2 inhibition augments the effcacy of a cancer vaccine. Clin Cancer Res 12: 214-222.
23. Lambright, ES, Amin, K, Wiewrodt, R, Force, SD, Lanuti, M, Propert, KJ et al. (2001). Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor effcacy. Gene Ther 8: 946-953.
24. Vile, RG, Nelson, JA, Castleden, S, Chong, H and Hart, IR (1994). Systemic gene therapy of murine melanoma using tissue specifc expression of the HSVtk gene involves an immune component. Cancer Res 54: 6228-6234.
25. Shibata, MA, Morimoto, J, Akamatsu, K and Otsuki, Y (2008). Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses. Med Mol Morphol 41: 34-43.
26. Suzuki, E, Sun, J, Kapoor, V, Jassar, AS and Albelda, SM (2007). Gemcitabine has signifcant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 6: 880-885.
27. Sica, A, Schioppa, T, Mantovani, A and Allavena, P (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
28. Kjaergaard, J and Shu, S (1999). Tumor infltration by adoptively transferred T cells is independent of immunologic specifcity but requires down-regulation of L-selectin expression. J Immunol 163: 751-759.
29. Cohen, PA, Peng, L, Kjaergaard, J, Plautz, GE, Finke, JH, Koski, GK et al. (2001). T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 21: 215-248.
30. Nowak, AK, Robinson, BW and Lake, RA (2002). Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358.
31. Spisek, R and Dhodapkar, MV (2007). Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 6: 1962-1965.
32. Obeid, M, Tesniere, A, Ghiringhelli, F, Fimia, GM, Apetoh, L, Perfettini, JL et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
33. Apetoh, L, Ghiringhelli, F, Tesniere, A, Criollo, A, Ortiz, C, Lidereau, R et al. (2007). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47-59.
34. Vo, DD, Prins, RM, Begley, JL, Donahue, TR, Morris, LF, Bruhn, KW et al. (2009). Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 69: 8693-8699.
35. Ramakrishnan, R, Assudani, D, Nagaraj, S, Hunter, T, Cho, HI, Antonia, S et al. (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120: 1111-1124.
36. Arlt, A, Gehrz, A, Müerköster, S, Vorndamm, J, Kruse, ML, Fölsch, UR et al. (2003). Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251.
37. Jones, DR, Broad, RM, Madrid, LV, Baldwin, AS Jr and Mayo, MW (2000). Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 70: 930-6; discussion 936.
38. Haefner, B (2002). NF-kappa B: arresting a major culprit in cancer. Drug Discov Today 7: 653-663.
39. Machiels, JP, Reilly, RT, Emens, LA, Ercolini, AM, Lei, RY, Weintraub, D et al. (2001). Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697.
40. Yu, B, Kusmartsev, S, Cheng, F, Paolini, M, Nefedova, Y, Sotomayor, E et al. (2003). Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 9: 285-294.
41. Prell, RA, Gearin, L, Simmons, A, Vanroey, M and Jooss, K (2006). The anti-tumor effcacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 55: 1285-1293.
42. Garnett, CT, Schlom, J and Hodge, JW (2008). Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14: 3536-3544.
43. Merritt, RE, Mahtabifard, A, Yamada, RE, Crystal, RG and Korst, RJ (2003). Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 126: 1609-1617.
44. Wilderman, MJ, Sun, J, Jassar, AS, Kapoor, V, Khan, M, Vachani, A et al. (2005). Intrapulmonary IFN-β gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 65: 8379-8387.
45. Lin, KY, Guarnieri, FG, Staveley-O'Carroll, K F, Levitsky, HI, August, JT, Pardoll, DM et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
46. Fitzpatrick, DR, Bielefeldt-Ohmann, H, Himbeck, RP, Jarnicki, AG, Marzo, AL and Robinson, BW (1994). Transforming growth factor-β: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infltrating T-cells in malignant mesothelioma. Growth Factors 11: 29-44.
47. Wilderman, MJ, Kim, S, Gillespie, CT, Sun, J, Kapoor, V, Vachani, A et al. (2006). Blockade of TNF-α decreases both infammation and effcacy of intrapulmonary Ad.IFNβ immunotherapy in an orthotopic model of bronchogenic lung cancer. Mol Ther 13: 910-917.
48. Brin, E, Atencio, I, Helmich, BK, Maneval, D and Laface, D (2006). Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma. Cancer Gene Ther 13: 664-675.
49. Smythe, WR, Hwang, HC, Amin, KM, Eck, SL, Davidson, BL, Wilson, JM et al. (1994). Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54: 2055-2059.
50. + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 65: 11752-11761.